kaiyun(Öйú)¹Ù·½ÍøÕ¾-¿ªÔÆÌåÓý¹Ù·½Èë¿Ú

¡¾Âö²¬Ò½Ò©¡¿MedBio|7365-45-9|HEPES¼¼Êõ×ÊÁÏ

2021-03-09

HEPESÖÐÎıðÃû£ºN-(2-ôÇÒÒ»ù)ßßàº-N'-2-ÒÒÍé»ÇËá | 4-ôÇÒÒ | N-2-ôÇÒÒ»ùßßàº-N'-2-ÒÒ»ÇËá(HEPES) | 4-(2-ôÇÒÒ»ù)-1-ßßົù]ÒÒ»ÇËá | N-2-ôÇÒÒ»ùßßàº-N'-2-ÒÒ»ÇËá | 4-(2-ôÇÒÒ»ù)-1-ßßàºÒÒ»ÇËá | ôÇÒÒ»ùßßàºÒÒ»ÇËá | N-(2-ôÇÒÒ»ù)ßßàº-N¡¯-2-ÒÒÍé»ÇËá

 

1¡¢4-ôÇÒÒ»ùßßàºÒÒ»ÇËáÎïÀí²ÎÊý£º

³£ÓÃÃû

4-ôÇÒÒ»ùßßàºÒÒ»ÇËá

Ó¢ÎÄÃû

HEPES

CASºÅ

7365-45-9

·Ö×ÓÁ¿

238.305

ÃܶÈ

1.3¡À0.1 g/cm3

·Ðµã

ÎÞ×ÊÁÏ

·Ö×Óʽ

C8H18N2O4S

ÈÛµã

234-238 ¡ãC

ÉÁµã

ÎÞ×ÊÁÏ

 

 

 

2¡¢4-ôÇÒÒ»ùßßàºÒÒ»ÇËáÓÃ;£º

HEPES ÊÇÒ»ÖÖÁ½ÐÔÀë×Ó»¯Ñ§»º³å¼Á£¬¹ã·ºÓ¦ÓÃÓÚϸ°ûÅàÑø¡£HEPES ÔÚ pH ֵΪ 6.8 ÖÁ 8.2 ʱΪÓÐЧµÄ»º³åÒº¡£HEPES ÊÇÈÜøÌåÉúÎï·¢ÉúµÄÓÐЧÓÕµ¼¼Á¡£

3¡¢4-ôÇÒÒ»ùßßàºÒÒ»ÇËáÎïÀí»¯Ñ§ÐÔÖÊ£º

ÃÜ¶È 1.3¡À0.1 g/cm3
ÈÛµã 234-238 ¡ãC
·Ö×Óʽ C8H18N2O4S
·Ö×ÓÁ¿ 238.305
¾«È·ÖÊÁ¿ 238.098724
PSA 89.46000
LogP -2.67
Íâ¹ÛÐÔ×´ °×É«½á¾§·ÛÄ©
ÕÛÉäÂÊ 1.543
´¢´æÌõ¼þ

ÃÜ·âÓÚ2-8?CÒõÁ¹¸ÉÔï»·¾³¡£

Îȶ¨ÐÔ

Èç¹û×ñÕÕ¹æ¸ñʹÓúʹ¢´æÔò²»»á·Ö½â¡£

Ë®ÈܽâÐÔ Soluble
·Ö×ӽṹ

1¡¢ Ħ¶ûÕÛÉäÂÊ£º56.69

2¡¢ Ħ¶ûÌå»ý£¨m3/mol£©£º179.7

3¡¢ µÈÕűÈÈÝ£¨90.2K£©£º487.2

4¡¢ ±íÃæÕÅÁ¦£¨dyne/cm£©£º53.9

5¡¢ ¼«»¯ÂÊ£¨10 -24cm 3£©£º22.47

¼ÆË㻯ѧ

1.ÊèË®²ÎÊý¼ÆËã²Î¿¼Öµ£¨XlogP£©:-4

2.Çâ¼ü¹©ÌåÊýÁ¿:2

3.Çâ¼üÊÜÌåÊýÁ¿:6

4.¿ÉÐýת»¯Ñ§¼üÊýÁ¿:5

5.»¥±äÒì¹¹ÌåÊýÁ¿:ÎÞ

6.ÍØÆË·Ö×Ó¼«ÐÔ±íÃæ»ý89.5

7.ÖØÔ­×ÓÊýÁ¿:15

8.±íÃæµçºÉ:0

9.¸´ÔÓ¶È:267

10.Í¬Î»ËØÔ­×ÓÊýÁ¿:0

11.È·¶¨Ô­×ÓÁ¢¹¹ÖÐÐÄÊýÁ¿:0

12.²»È·¶¨Ô­×ÓÁ¢¹¹ÖÐÐÄÊýÁ¿:0

13.È·¶¨»¯Ñ§¼üÁ¢¹¹ÖÐÐÄÊýÁ¿:0

14.²»È·¶¨»¯Ñ§¼üÁ¢¹¹ÖÐÐÄÊýÁ¿:0

15.¹²¼Û¼üµ¥ÔªÊýÁ¿:1

 

4¡¢4-ôÇÒÒ»ùßßàºÒÒ»ÇËáÉú̬ѧÊý¾Ý£º

¸ÃÎïÖʶԻ·¾³¿ÉÄÜÓÐΣº¦£¬¶ÔË®ÌåÓ¦¸øÓèÌØ±ð×¢Òâ¡£

5¡¢4-ôÇÒÒ»ùßßàºÒÒ»ÇËáÐÔÖÊÓëÎȶ¨ÐÔ£º

Èç¹û×ñÕÕ¹æ¸ñʹÓúʹ¢´æÔò²»»á·Ö½â¡£

6¡¢4-ôÇÒÒ»ùßßàºÒÒ»ÇËáÖü´æ·½·¨£º

ÃÜ·âÓÚ2-8?CÒõÁ¹¸ÉÔï»·¾³¡£

7¡¢Í¬Àà²úÆ·Áбí£º

Æ·ÅÆ

»õºÅ

ÖÐÎÄÃû³Æ

Ó¢ÎÄÃû³Æ

CAS

°ü×°

´¿¶È

MedBio

MED17466

Arginase inhibitor 1

Arginase inhibitor 1

1345808-25-4

2mg

¡Ý98%

Æ·ÅÆ

»õºÅ

ÖÐÎÄÃû³Æ

Ó¢ÎÄÃû³Æ

CAS

°ü×°

´¿¶È

MedBio

MED17883

PF 1022A

PF 1022A

133413-70-4

5mg

¡Ý98%

Æ·ÅÆ

»õºÅ

ÖÐÎÄÃû³Æ

Ó¢ÎÄÃû³Æ

CAS

°ü×°

´¿¶È

MedBio

MED17820

BMS 195614

BMS 195614

253310-42-8

50mg

¡Ý98%

Æ·ÅÆ

»õºÅ

ÖÐÎÄÃû³Æ

Ó¢ÎÄÃû³Æ

CAS

°ü×°

´¿¶È

MedBio

MED17988

1,3-PBIT (dihydrobromide)

1,3-PBIT (dihydrobromide)

200716-66-1

100mg

¡Ý98%

Æ·ÅÆ

»õºÅ

ÖÐÎÄÃû³Æ

Ó¢ÎÄÃû³Æ

CAS

°ü×°

´¿¶È

MedBio

MED17934

Ataciguat

Ataciguat

254877-67-3

1mg

¡Ý98%

Æ·ÅÆ

»õºÅ

ÖÐÎÄÃû³Æ

Ó¢ÎÄÃû³Æ

CAS

°ü×°

´¿¶È

MedBio

MED17715

Diethylmaleate

Diethylmaleate

141-05-9

100ul

¡Ý98%

Æ·ÅÆ

»õºÅ

ÖÐÎÄÃû³Æ

Ó¢ÎÄÃû³Æ

CAS

°ü×°

´¿¶È

MedBio

MED17898

1,4-DPCA

1,4-DPCA

331830-20-7

25mg

¡Ý98%

Æ·ÅÆ

»õºÅ

ÖÐÎÄÃû³Æ

Ó¢ÎÄÃû³Æ

CAS

°ü×°

´¿¶È

MedBio

MED17587

kb-NB77-78

kb-NB77-78

1350622-33-1

10mg

¡Ý98%

Æ·ÅÆ

»õºÅ

ÖÐÎÄÃû³Æ

Ó¢ÎÄÃû³Æ

CAS

°ü×°

´¿¶È

MedBio

MED17833

Deoxynivalenol

Deoxynivalenol

51481-10-8

500ug

¡Ý98%

Æ·ÅÆ

»õºÅ

ÖÐÎÄÃû³Æ

Ó¢ÎÄÃû³Æ

CAS

°ü×°

´¿¶È

MedBio

MED17962

D-NMAPPD

D-NMAPPD

35922-06-6

50mg

¡Ý98%

 

8¡¢4-ôÇÒÒ»ùßßàºÒÒ»ÇËáÎÄÏ×£º

Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth.
PLoS Biol. 12(1) , e1001758, (2014)

Functional consequence of the MET-T1010I polymorphism in breast cancer.
Oncotarget 6(5) , 2604-14, (2015)

Immunomodulation by the Pseudomonas syringae HopZ type III effector family in Arabidopsis.
PLoS ONE 9(12) , e116152, (2014)

9¡¢4-ôÇÒÒ»ùßßàºÒÒ»ÇËáÓ¢ÎıðÃû£º

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
hepesfreeacid
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
HEPES.1/2Na
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
EIT hydrobromide
hepes solution
1-Piperazineethanesulfonic acid, 4-(2-hydroxyethyl)-
4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid
GOOD'S BUFFER
HEPES
HEPES BUFFER PH 8.0
2-[4-(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic acid
EINECS 230-907-9
HEPES,1M solution
MFCD00006158
»õºÅ ²úÆ·Ãû³Æ Æ·ÅÆ ¹æ¸ñÐͺаü×° Ŀ¼¼Û ÊýÁ¿ ¹ºÎï³µ
MED80020 HEPES ,7365-45-9 MedBio ¡Ý99% 500g ?679.00
MED80020 HEPES ,7365-45-9 MedBio ¡Ý99% 100g ?190.00
MED80020 HEPES ,7365-45-9 MedBio ¡Ý99% 5g ?100.00
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿